 |
|
Hepatitis C in Organ Donors and Heart Transplant Recipients—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: We agree with Drs Taylor and Fontana that the safety and efficacy of transplanting organs from donors seropositive for HCV might vary with different organ type. Although our study suggests that the use of HCV-positive donors conveys an early and sustained survival disadvantage among heart transplant recipients, other studies suggest similar patient survival among liver transplant recipients1 and differences in survival only after 3 to 5 years posttransplant among kidney transplant recipients.2 In contrast, little is known about the consequences of transplanting lung, pancreas, and intestinal allografts from HCV-positive donors.
While receipt of a heart from an HCV-positive donor results in inferior outcomes among heart transplant recipients, it might, nonetheless, be a practical option for candidates otherwise facing imminent death. Furthermore, outcomes associated with the use of HCV-positive donors should be assessed as better therapies for HCV are identified and the interactions between host immunity and the natural . . . [Full Text of this Article]
Leanne B. Gasink, MD, MSCE
leanne.gasink@uphs.upenn.edu
Emily A. Blumberg, MD;
A. Russell Localio, PhD;
Ebbing Lautenbach, MD, MPH, MSCE
University of Pennsylvania
Philadelphia
Shashank S. Desai, MD
Inova Fairfax Hospital
Falls Church, Va
Ajay K. Israni, MD, MS
University of Minnesota
Minneapolis
RELATED LETTER
Hepatitis C in Organ Donors and Heart Transplant Recipients
Ryan M. Taylor and Robert J. Fontana
JAMA. 2007;297(7):696.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Hepatitis C Virus Seropositivity in Organ Donors and Survival in Heart Transplant Recipients
Leanne B. Gasink, Emily A. Blumberg, A. Russell Localio, Shashank S. Desai, Ajay K. Israni, and Ebbing Lautenbach
JAMA. 2006;296(15):1843-1850.
ABSTRACT
| FULL TEXT
|
